Biobot Surgical Secures S$10 Million Series C Investment Co-led by ClavystBio

Biobot Surgical, a Singapore-based medical device developer specializing in minimally invasive surgical robotics, has secured S$10 million in Series C funding, co-led by ClavystBio and supported by existing investors. The investment, announced in April 2026, marks a significant step in the company’s efforts to advance its robotic-assisted surgery platform toward regulatory approval and commercial deployment in key Asian markets.

The Series C round brings Biobot Surgical’s total funding to date to over S$25 million, according to company disclosures. ClavystBio, a Singapore-based life sciences venture firm focused on early- to growth-stage healthcare innovations, took a lead role in structuring and executing the investment alongside Biobot’s current backers, including SEEDS Capital and other strategic healthcare investors. The terms of the deal, including valuation and equity stake, were not disclosed publicly.

Biobot Surgical’s core technology centers on a modular robotic system designed to enhance precision and reduce invasiveness in laparoscopic and endoscopic procedures. The platform integrates haptic feedback, AI-assisted navigation, and ergonomic instrument control to support surgeons in complex soft-tissue operations. The company has previously completed preclinical testing and pilot clinical studies in collaboration with Singapore General Hospital and National University Hospital, with data indicating improved dexterity and reduced operative times compared to conventional laparoscopic tools.

The latest funding will be used primarily to complete regulatory documentation for submission to Singapore’s Health Sciences Authority (HSA) and to pursue CE marking under the European Union’s Medical Devices Regulation (MDR). Biobot Surgical also plans to initiate first-in-human trials in selected Southeast Asian hospitals by late 2026, pending regulatory clearance. A portion of the capital will support scaling manufacturing readiness and expanding its intellectual property portfolio, particularly around proprietary actuator designs and software algorithms for motion compensation.

ClavystBio’s involvement underscores continued investor confidence in Asia’s growing medtech innovation ecosystem. The firm has previously backed several Singapore- and Malaysia-based health technology startups, with a focus on companies bridging engineering rigor and clinical applicability. In a statement, ClavystBio’s managing partner noted that Biobot Surgical’s approach addresses a critical gap in accessible robotic surgery, particularly for community hospitals and ambulatory surgical centers that lack access to high-cost systems from established global players.

“We see strong potential in Biobot’s modular design to lower the barrier to entry for robotic-assisted surgery without compromising on performance,” said the partner. “Their focus on real-world clinical workflows and cost-effective scalability aligns with the unmet needs we observe across Southeast Asia’s healthcare infrastructure.”

The investment reflects broader trends in private capital flowing into healthcare innovation across Southeast Asia, where governments and private institutions are increasing support for local medtech development. Initiatives such as Singapore’s Research, Innovation and Enterprise 2025 (RIE2025) plan and Malaysia’s National Medical Device Policy have created funding pathways and regulatory sandboxes to accelerate homegrown innovation. Biobot Surgical has benefited from earlier grants under Singapore’s Startup SG Founder and TechBridge programs, which helped de-risk early-stage development.

Industry analysts note that while the global surgical robotics market remains dominated by a few large multinational corporations, there is growing interest in alternative models that offer lower total cost of ownership and greater adaptability to diverse clinical settings. Companies like Biobot Surgical, Vicarious Surgical, and Medtronic’s Hugo RAS system represent different approaches to this challenge, though Biobot’s emphasis on modularity and open-architecture software distinguishes it from more proprietary systems.

Bot Surgical has not yet announced a timeline for seeking FDA clearance or pursuing U.S. Market entry, indicating that its near-term strategy remains focused on establishing proof of value and regulatory compliance in Asia and Europe. The company’s leadership includes biomedical engineers and former clinicians from A*STAR and Nanyang Technological University, with ongoing collaboration from surgical advisors at major public hospitals in Singapore.